{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:39:20Z","timestamp":1793662760017,"version":"4.5.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.xkme.2020.06.008","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T11:44:19Z","timestamp":1597059859000},"page":"589-599.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era"],"prefix":"10.1016","volume":"2","author":[{"given":"Borut","family":"Cizman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen T.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Refoios","family":"Camejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Casillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harjeet","family":"Dhillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jipan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Zuckerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Coyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.xkme.2020.06.008_bib1","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"20","key":"10.1016\/j.xkme.2020.06.008_bib2","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Drueke","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.xkme.2020.06.008_bib3","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A\u00a0trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.xkme.2020.06.008_bib4","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xkme.2020.06.008_bib5","unstructured":"FDA. FDA Drug Safety Communication: modified dosing recommendations to improve the safety of erythropoiesis-stimulating agents (ESAs) in chronic kidney disease, https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-modified-dosing-recommendations-improve-safe-use-erythropoiesis. 2011. Accessed December 11, 2019."},{"issue":"1","key":"10.1016\/j.xkme.2020.06.008_bib7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/j.ajkd.2015.06.030","article-title":"New treatment approaches for the anemia of CKD","volume":"67","author":"Bonomini","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1016\/j.xkme.2020.06.008_bib8","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.ajkd.2016.05.031","article-title":"Spectrum and burden of erythropoiesis-stimulating agent hyporesponsiveness among contemporary hemodialysis patients","volume":"68","author":"Luo","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"1 suppl 1","key":"10.1016\/j.xkme.2020.06.008_bib9","first-page":"Svii","article-title":"US Renal Data System 2014 Annual Data Report: epidemiology of kidney disease in the United States","volume":"66","author":"Saran","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.xkme.2020.06.008_bib10","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12882-015-0138-x","article-title":"Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients","volume":"16","author":"Sibbel","year":"2015","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.xkme.2020.06.008_bib11","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/1471-2369-14-200","article-title":"Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients","volume":"14","author":"Suttorp","year":"2013","journal-title":"BMC Nephrol"},{"issue":"4","key":"10.1016\/j.xkme.2020.06.008_bib12","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/pds.3755","article-title":"Factors precipitating erythropoiesis-stimulating agent responsiveness in a European haemodialysis cohort: case-crossover study","volume":"24","author":"Gillespie","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.xkme.2020.06.008_bib13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/j.ajkd.2014.06.020","article-title":"A\u00a0randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent\u00a0hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial","volume":"65","author":"Johnson","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.xkme.2020.06.008_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000477217","article-title":"Erythropoietin hyporesponsiveness in dialysis patients: possible role of statins","volume":"46","author":"Hasegawa","year":"2017","journal-title":"Am J Nephrol"},{"issue":"2","key":"10.1016\/j.xkme.2020.06.008_bib15","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013981","article-title":"Statin therapy and erythropoiesis-stimulating agent hyporesponsiveness in patients with nondialysis chronic kidney disease: a retrospective study in Beijing, China","volume":"98","author":"Sui","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.xkme.2020.06.008_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000350583","article-title":"Higher doses of erythropoietin-stimulating agents and hyporesponsiveness to their effects are associated with increased mortality among prevalent hemodialysis patients","volume":"36","author":"Nishio","year":"2013","journal-title":"Blood Purif"},{"issue":"7","key":"10.1016\/j.xkme.2020.06.008_bib17","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1093\/ndt\/gfs007","article-title":"Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients","volume":"27","author":"Minutolo","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.xkme.2020.06.008_bib18","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/ndt\/gft033","article-title":"Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement","volume":"28","author":"Locatelli","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.xkme.2020.06.008_bib19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.xkme.2020.06.008_bib20","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/s12882-017-0745-9","article-title":"Evaluating the effectiveness of IV iron dosing for anemia management in common clinical practice: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"18","author":"Robinson","year":"2017","journal-title":"BMC Nephrol"},{"issue":"3","key":"10.1016\/j.xkme.2020.06.008_bib21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1053\/ajkd.2002.34881","article-title":"Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients","volume":"40","author":"Besarab","year":"2002","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1016\/j.xkme.2020.06.008_bib22","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1056\/NEJM199808273390902","article-title":"Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients","volume":"339","author":"Kaufman","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.xkme.2020.06.008_bib23","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1053\/j.ajkd.2008.12.040","article-title":"Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients","volume":"53","author":"Kalantar-Zadeh","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.xkme.2020.06.008_bib24","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ekir.2019.03.016","article-title":"Cardiovascular event rates among hemodialysis patients across geographical regions-a snapshot from the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"4","author":"Stirnadel-Farrant","year":"2019","journal-title":"Kidney Int Rep"},{"issue":"7","key":"10.1016\/j.xkme.2020.06.008_bib25","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1080\/08860220903082606","article-title":"Hyporesponsiveness to erythropoietin therapy in hemodialyzed patients: potential role of prohepcidin, hepcidin, and inflammation","volume":"31","author":"Malyszko","year":"2009","journal-title":"Ren Fail"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S259005952030162X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S259005952030162X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:19:57Z","timestamp":1762910397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S259005952030162X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S259005952030162X"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2020.06.008","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2020.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}